Hoth Therapeutics Offers Update On Its Novel Peptide COVID-19 Therapeutic HT-002 Preclinical Studies: 1 Of 3 Peptide Candidates Has Demonstrated Low Level Viral Inhibition Assay With No Toxicity
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.